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To the Editor:
Patients with systemic lupus erythematosus (SLE) are at
increased risk of premature atherosclerosis, mediated by endothe-
lial dysfunction and increased arterial stiffness [1]. The latter, most
commonly assessed using carotid-femoral pulse wave velocity, is
increased in patients with SLE and is associated with cardiovascular
risk factors [1]. Recently, a more sensitive measure of arterial
stiffness (effective arterial elastance; Ea), and ventricular-arterial
coupling (ratio of arterial and end-systolic ventricular elastance;
Ea/Ees) demonstrated incremental prognostic value in patients
with chronic heart failure [2]. We aimed to assess the potential of Ea
and Ea/Ees as novel biomarkers of cardiovascular risk in SLE women
without ischemic heart disease.
Womenwho satisﬁed the revised American College of Rheumatol-
ogy classiﬁcation criteria for SLE were prospectively recruited from
the rheumatology clinics, as described previously [3]. Patients with
recent active ﬂares, ischemic heart disease (all patients underwent
nuclear stress perfusion imaging as part of the study), cardiomyo-
pathies (including myocarditis) and valvular heart disease of ≥
moderate severity were excluded. Cardiovascular risk was deﬁned
as history of hypertension, hyperlipidemia, diabetes mellitus, current
tobacco use, cerebrovascular events, family history of coronary artery
disease and secondary anti-phospholipid syndrome. Age-matched
control women were recruited from the community. Left ventricular
mass, diastolic function and systolic ejection fractionwere assessedwith
echocardiography; Ea was estimated as 0.9 x (arm-cuff systolic
pressure/Doppler stroke volume) and Ees was calculated by the well-
validated approach of using arm-cuff pressures, Doppler stroke
volumes, ejection fraction, pre-ejection and systolic periods [4,5]. The
studywas conducted in accordancewith the Declaration of Helsinki and
approved by the local research ethics committee. Written informed
consent was obtained from all participants.
Continuous variables were presented in mean±SD or median
[interquartile range] and compared using either the Student t test or
Mann-Whitney U test, as appropriate. The mean differences in Ea and
Ea/Ees were adjusted for age, systolic ejection fraction and systolic
blood pressure. We assessed associations using the Pearson (r) or
Spearman (ρ) correlation, as appropriate. All statistical analyses were
performed with the SPSS version 19 (SPSS Inc, Chicago, USA). A
two-sided P b0.05 was considered statistically signiﬁcant.
Forty-eight patients with SLE (43±9 years old; disease duration of
14±6 years; 1 [0,2] risk factors) and 20 control women (42±9 years
old) were recruited. There were no differences in left ventricular
mass, diastolic function and Ees between SLE and control women
(PN0.50 for all; Table 1). Compared to control individuals, patients
with SLE had lower systolic ejection fraction, albeit a small difference
(71±8 versus 75±7%; P=0.04). Despite similar systolic blood
pressure compared with control women (116±12 versus 119±16
mmHg; P=0.52), patients with SLE had increased Ea (1.77±0.56
versus 1.37±0.27 mmHg/mL; adjusted mean difference 0.30 mmHg/
mL, 95% conﬁdence interval [CI] 0.08 to 0.53mmHg/mL, Pb0.001) and
Ea/Ees (0.61±0.18 versus 0.50±0.07; adjusted mean difference 0.06,
95% CI 0.01 to 0.12, P=0.04). Furthermore, Ea was associated with
increasing cardiovascular risk (ρ=0.35; P=0.02), systolic blood
pressure (r=0.55, Pb0.001) and duration of prednisolone use
(ρ=0.33, P=0.03).
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Table 1
Characteristics of control individuals and patients with systemic lupus erythematosus
(SLE).
Control
Individuals
(n = 20)
Patients with
SLE
(n = 48)
P
value
Clinical characteristic
Age, years 42±9 43±9 0.71
History of hypertension 1 (5) 12 (25) 0.06
History of diabetes mellitus 0 2 (4) 0.35
History of hyperlipidemia 0 10 (21) 0.03
Current tobacco use 1 (5) 4 (8) 0.63
Family history of coronary artery disease 5 (25) 7 (15) 0.30
History of cerebrovascular event 0 7 (15) 0.07
Presence of secondary anti-
phosphoplipid syndrome
- 12 (25) -
Duration of SLE diagnosed, years - 14±6 -
SLICC/ACR damage index¶ - 0 [0,1] -
Current prednisolone use - 25 (52) -
Body mass index, kg/m2 23.8±3.7 23.4±5.0 0.76
Systolic blood pressure, mmHg 116±12 119±16 0.52
Low density lipoprotein cholesterol,
mmol/L
- 3.0±0.7 -
High density lipoprotein cholesterol,
mmol/L
- 1.3±0.4 -
Echocardiographic characteristics
Indexed left ventricular mass, g/m2 57 [52.72] 60 [52,77] 0.46
Diastolic function E/e’ 6.9 [5.7,8.0] 6.2 [4.9,8.3] 0.48
Systolic ejection fraction, % 75±7 71±8 0.04
Effective arterial elastance (Ea),
mmHg/mL
1.34 [1.25,1.49] 1.64
[1.42,1.95]
b0.001
End-systolic elastance (Ees), mmHg/mL 2.82
[2.36,3.19]
3.03
[2.59,3.49]
0.18
Ea/Ees 0.49
[0.45,0.55]
0.56
[0.51,0.64]
b0.001
Results are presented in mean±SD, median [25th, 75th percentiles] or n (%).
¶ SLICC/ACR Systemic Lupus International Collaborating Clinics/American College of
Rheumatology damage index assessed organ damage in 12 systems with a maximum
score of 47.
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Over 3 years of follow-up (median 31 [17,37] months), 8% of
patients with SLE developed cardiovascular events (event rate 3.2 per
100 person-years; non-fatal myocardial infarction, n=2; stroke, n=1;
signiﬁcant coronary artery disease, n=1). Importantly, compared to
control individuals and patients without events, SLE patients with
cardiovascular events had increased Ea (1.33 [1.25,1.49] versus 1.59
[1.40,1.93] versus 2.10 [1.59,2.98] mmHg/mL, respectively; Pb0.001)
and Ea/Ees (0.49 [0.45,0.55] versus 0.55 [0.51,0.64] versus 0.59
[0.55,1.15], respectively; Pb0.01).
By design, we had excluded patients with ischemic heart disease
and cardiomyopathies, as the role of non-invasive vascular imaging
will be of greater relevance in these patients. Therefore, it was not
surprising that we did not see any difference in Ees, a marker of
ventricular stiffness, between SLE and control women. This was also
supported by the similar left ventricular mass and diastolic function
between SLE and control women. The small difference in systolic
ejection fraction was likely an event of chance and not of important
clinical signiﬁcance. Conversely, Ea was signiﬁcantly increased in
patients with SLE compared to control women despite similar and
normal blood pressures. The combination of these changes account for
the small magnitude of Ea/Ees effect sizes. The association between
Ea, Ea/Ees and adverse events is promising but we acknowledge this is
exploratory and will require further validation in larger cohorts with
longer follow-up.
In conclusion, arterial elastance and ventricular-arterial coupling
are associated with increased cardiovascular risk and are potential
novel markers of adverse cardiovascular events in patients with SLE.
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Multivessel coronary artery disease (MVD) in ST-segment eleva-
tion myocardial infarction (STEMI) is a common clinical condition
encountered by interventional cardiologists and it is associated with
poorer clinical outcomes than single-vessel disease [1]. Current
guidelines recommend culprit-vessel only revascularization (CVR)
during primary angioplasty, except in patients that are hemodynami-
cally unstable [2]. Several recent studies have reported promising
results from CVR followed by elective second-stage PCI at non-infarct
related arteries with signiﬁcant stenosis. However, there are insufﬁ-
cient data on the long-term outcomes of staged PCI in these patients.
We investigated the long-term clinical outcomes of a staged PCI
strategy compared to ad hoc PCI and CVR in patients with STEMI and
MVD who underwent primary PCI.
We enrolled 575 consecutive patients with STEMI and MVD who
visited Chonnam National University Hospital from January 2006 to
July 2009. All patients underwent primary PCI within 120 min after
being admitted to thehospital.We selected474patients after exclusionof
patients who presented with cardiogenic shock. Patients were divided
into three groups based on the initial interventional strategy: staged PCI
(initial index intervention and secondaryelective stagedPCI during index
hospitalization, n = 252); ad hoc (simultaneous infarct-related and non
infarct-related artery intervention during the index procedure, n = 67);
and culprit-vessel only PCI (CVR, n = 155). The primary endpoint was
composite outcome including death from all causes, myocardial infarc-
tion (MI) and repeat PCI during 3-year clinical follow-upvisits. Repeat PCI
included target lesion revascularization, target vessel revascularization
and non-target vessel revascularization. Three-year composite outcomes
and death from all causes or MI were evaluated using the Kaplan–Meier
analysis and compared using a log-rank test. Cox regression analysis was
used to identify the clinical impact of staged PCI with complete
revascularization (CR) adjusted with clinically relevant covariates. All
variables were considered signiﬁcant when the p-value was b0.05.
There were no signiﬁcant differences in baseline and angiographic
characteristics among groups except formore aged persons (staged vs. ad
hoc vs. CVR; 68.8 ± 10.8 vs. 65.5 ± 12.8 vs. 70.7 ± 13.7, p = 0.012), more
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